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INTRODUCTION
Gain-of-function mutations in BRAF have been identifi ed in various cancers (Davies et al., 2002) . Notably, BRAF somatic mutations have been observed in 66% of malignant melanomas (Davies et al., 2002) , and these exhibit a valine-to-glutamate substitution (V600E), which renders BRAF constitutively active. This prevalence of BRAF mutations has prompted efforts to develop inhibitors of the mutated BRAF (Sabbatino et al., 2013; Holderfi eld et al., 2014) . Selective BRAF inhibitors including vemurafenib and dabrafenib displayed potent antineoplastic activities in tumor cells bearing BRAF V600E, whereas lacking their activity in cell lines that express wildtype (WT) BRAF. It has been demonstrated clinical benefi ts in patients with BRAF V600E melanoma McGettigan, 2014) . We also recently reported UAI-201 (also described as UI-152) as a potent ATP-competitive inhibitor of RAF proteins (Kim et al., 2012) . UAI-201 was more than 1,000-fold more selective in inhibiting the proliferation of tumor cell lines bearing the BRAF-V600E mutation compared with cells bearing wild-type BRAF (Kim et al., 2012) .
However, intrinsic and acquired resistance limits the therapeutic benefi ts of these oncogenic BRAF inhibitors Rizos et al., 2014) . The mechanisms that underlie the therapeutic resistance of melanoma include the overexpression of MAP kinase kinase kinase 8 (MAP3K8; COT) (Johannessen et al., 2010) , mutations in N-Ras, and PDGFRβ overexpression (Nazarian et al., 2010) . Our previous study also implicated the upregulation of N-Ras as a key mechanism of acquired resistance to oncogenic BRAF inhibitors
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In general, the feedback mechanism may be dysfunctional due to insensitivity of the mutant oncogene to normal regulation in some tumors. Actually, BRAF V600E is able to bypass the inhibitory effects of negative-feedback regulation induced by ERK. One potent inhibitor of the Raf/MAP kinase pathway is the Sprouty (Spry) protein (Yusoff et al., 2002) , which was fi rst identifi ed in a genetic screen of Drosophila (Hacohen et al., 1998) . Previous results have indicated that the MAPK pathway both transcriptionally upregulates Spry2 and posttranscriptionally attenuates its ability to inhibit MAPK signaling (Brady et al., 2009) . In particular, relief of feedback after targeted therapy may be viewed as a key contributor to therapeutic resistance (Chandarlapaty, 2012) . Consistent with this opinion, we previously showed that Raf-1 may be released from negative feedback inhibition by interacting with Spry2 in multi-drug-resistant Ras-NIH 3T3/Mdr cells (Ahn et al., 2011) .
A375P/Mdr cell lines with acquired resistance to BRAF inhibitors were generated by propagating parental A375P cells harboring BRAF-V600E in increasing concentrations of BRAF inhibitor to achieve chronic selection (Ahn and Lee, 2013) . On the contrary, SK-MEL-2 cell line expressing WT BRAF has an intrinsic resistance to BRAF inhibition because BRAF inhibitor lacked activity in cell lines that express WT BRAF. To further identify potential mechanisms of resistance to BRAF inhibitors, we investigated the role of Spry2 in the resistance to BRAF inhibitors using A375P/Mdr and SK-MEL-2 cells. This manuscript provides the fi rst evidence demonstrating that Spry2 exhibits strongly reduced expression in A375P/Mdr cells with acquired resistance to BRAF inhibitors. The present results demonstrated that long-term treatment with a BRAF inhibitor signifi cantly downregulated Spry2 in BRAF-V600E-positive cell lines, which was concomitant with the rebound activation of the MAPK pathway.
MATERIALS AND METHODS

Antibodies and reagents
Rabbit polyclonal anti-Spry2 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and anti-phospho-MEK and anti-phospho-ERK were purchased from Cell Signaling Technology (Danvers, MA, USA). SYBR Premix EX Taq II used for real-time PCR was obtained from Takara Korea Biomedical Inc. (Seoul, Korea). Dulbecco's modifi ed Eagle's medium (DMEM), fetal calf serum (FCS) and penicillin-streptomycin were purchased from GIBCO-Invitrogen (Carlsbad, CA, USA). Reagents for SDS-polyacrylamide gel electrophoresis were obtained from Bio-Rad (Hercules, CA, USA). PLX4720 was obtained from Selleck Chemicals (Houston, TX, USA). PLX4720 was dissolved in DMSO and freshly diluted for each experiment. The DMSO concentrations were less than 0.1% in all of the experiments.
Cell lines and cell culture
Melanoma cell lines (A375P and SK-MEL-2) were obtained from either the Korean Cell Line Bank (KCLB; Seoul, Korea) or YOUAI Co., Ltd. (Suwon-Si, Gyeonggi-Do, Korea). The development of BRAF inhibitor-resistant A375P melanoma cells (A375P/Mdr) was previously described (Ahn and Lee, 2013) .
All of the cell lines were maintained at 37 o C in DMEM supplemented with 10% FCS, penicillin-streptomycin, and glutamine. The A375P/Mdr cells were further propagated in growth medium containing 1 μM PLX4720. Before their use in the experiments, the A375P/Mdr cells were maintained in PLX4720-free culture medium and subcultured at least three times. For experimental purposes, the cells were cultured in 60-mm tissue culture dishes until they reached ~80% confl uency.
Plasmid DNA and siRNA transfection
The pCMV6 vector encoding full-length Spry2 cDNA was obtained from OriGene Technologies, Inc. (Rockville, MD, USA). For Spry2 knockdown, a pool of three target-specifi c Spry2 siRNAs was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The targeted sequences were the following: CCAUCCGAAACACCAAUGAtt, GCAACCAACUAAACAGUUAtt, and CCUUUGGACUUCAUGUAUAtt. The three targeted sequences of the siRNA used for the knockdown of Raf-1 were GGAACACAAAGGUAAGAAAtt, CCCAUGCCUUCACUUUCAAtt and GUUGCAGUAAAGAUCCUAAtt. A non-targeting siRNA (Santa Cruz Biotechnology, CA, USA) was used as a control. The cells were transiently transfected with either the siRNAs or pCMV6-Spry2 as indicated using Lipofectamine 2000 in Opti-minimal essential medium I (Invitrogen).
Cell growth assay
The cells were plated in quadruplicates in 96-well microliter plates (Costar, Cambridge, MA, USA) at a density of 5×10 3 cells/well and then treated with PLX4720 at 37 o C in a humidifi ed 5% CO 2 /95% air incubator. On day 3, the cells were incubated with MTT at 37 o C for 3 h. The absorbance of the samples against a background control (medium alone), which was used as a blank, was measured at 450 nm using a microliter plate (ELISA) reader (Molecular Devices, Sunnyvale, CA, USA).
RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)
The total RNA from BRAF inhibitor-sensitive and BRAF inhibitor-resistant melanoma cells was isolated with the RNeasy min kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Using a reverse transcriptase, cDNA was synthesized from 1 μg of total RNA. A 2-μl sample of cDNA was subjected to standard PCR amplifi cation with PCR MasterMix (Bioneer, Daejeon, Korea) to determine the expression of Spry2. The human β-actin primers were used as control primers for amplifi cation. The specifi city of the PCR products was confi rmed by 2% agarose gel electrophoresis. Realtime PCR was carried out with an Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using SYBR Premix EX Taq II. Aliquots of cDNA were used as a template for real-time PCRs containing either primers for Spry2, Raf-1 or primers for β-actin. The primers were synthesized by Bioneer (Daejeon, Korea) with the following oligonucleotide sequences: Spry2, 5'-GAGTCGTCTC-CAGCTCCGAAC-3' and 5'-AGCTCTGGCCTCCATCAGG-3'; Raf-1, 5'-GCTGTGAAAGGAGGACGTGT-3' and 5'-GGAGA-CACATGGGATTTTGG-3'. The temperature cycle profi le for the real-time PCRs was 95°C for 10 min and 40 cycles of 95°C for 30 s, 60°C for 1 min, and 72°C for 1 min. Melting curve analysis was also included using one cycle of 95°C for 1 min, http://dx.doi.org/10.4062/biomolther.2015.007 55°C for 30 s, and 95°C for 30 s to verify the specifi city of the amplifi ed PCR products. The real-time PCR data were normalized to differences in the β-actin levels through the 2-ΔΔCt method (Livak and Schmittgen, 2001 ).
Preparation of cell lysates and immunoblot analysis
Whole-cell lysates were prepared as follows: The cells were washed twice with ice-cold PBS and harvested by scraping cells into RIPA lysis buffer. For immunoblotting, the wholecell lysates were denatured in Laemmli sample buffer and resolved by SDS-polyacrylamide gel electrophoresis. The proteins were transferred to nitrocellulose, and immunoblot analysis was performed using the appropriate primary antibodies. The immune complexes on nitrocellulose were detected by the ECL-Plus chemiluminescent system (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Fluorescent images were captured using KODAK Image Station 4000R (Carestream Health, Inc., Rochester, NY, USA). Band intensities were quantifi ed using the Kodak Molecular Imaging software (version 4.5.0; Carestream Health, Inc.) .
RESULTS
Downregulation of Spry2 in cells resistant to BRAF inhibitors
Spry2 has previously been suggested as a negative regulator of the MAPK pathway through interaction with Raf-1 (Yusoff et al., 2002) . Our previous results also showed that Raf-1 may be released from negative feedback inhibition by interacting with Spry2 in multi-drug-resistant Ras-NIH 3T3/Mdr cells (Ahn et al., 2011) . In this study, reverse-transcriptional realtime PCR was used for determination of the mRNA expression levels of Spry2 in BRAF inhibitor-sensitive and BRAF inhibitorresistant melanoma cells. As shown in Fig. 1A , Spry2 expression was higher in A375P cells harboring the BRAF V600E mutation compared with wild-type BRAF-bearing cells (SK-MEL-2) resistant to BRAF inhibitors. Most interestingly, Spry2 exhibited strongly reduced expression in A375P/Mdr cells with acquired resistance to BRAF inhibitors. Agarose gel separation ensured the product specifi city (Fig. 1B) .
Reversal of BRAF inhibitor sensitivity by Spry2 overexpression in A375P/Mdr cells
To test the hypothesis that Spry2 plays a critical role in the acquired resistance to BRAF inhibitors, we examined the difference in sensitivity to the BRAF inhibitor PLX4720 between mock-and Spry2-transfecetd cells. Three cell lines with differing resistance to BRAF inhibitors were grown on a 96-well plate, and the numbers of viable cells were quantifi ed using a colorimetric assay. The overexpression of Spry2 was confi rmed by immunoblotting analysis (Fig. 2A) . Also, we confi rmed that, although faint, a band for Spry2 is present in A375P cell lines. In A375P/Mdr and SK-MEL-2 cell lines, the endogenous protein level of Spry2 was too low to detect in immunoblot analysis. As shown in Fig. 2B , Spry2 overexpression partially restored sensitivity to the BRAF inhibitor PLX4720 in two BRAF inhibitor-resistant cell lines (SK-MEL-2 and A375P/ Mdr), irrespective of their BRAF mutational status. Conversely, Spry2 overexpression had no effect on PLX4720 sensitivity in the BRAF inhibitor-sensitive A375P cells, which showed strong expression of endogenous Spry2. These results imply that Spry2 plays a positive role in the growth inhibition induced by BRAF inhibitors. However, Spry2 overexpression in A375P/ Mdr cells resulted in no signifi cant change in the levels of pERK or pMEK (Fig. 2C ).
Eff ect of RNAi targeting Spry2 on sensitivity to BRAF inhibitors
We then silenced Spry2 by siRNA-mediated knockdown to further assess a potential role of Spry2. The Spry2 siRNA transfection in A375P and SK-MEL-2 cells signifi cantly decreased Spry2 expression compared with the controls. In case of A375P/Mdr cells with a very weak expression of Spry2, siRNA-mediated Spry2 knockdown was not effi cient as much as in other two cell lines. We found that the siRNA-mediated Spry2 knockdown in A375P cells, which exhibit strong Spry2 expression, partially conferred PLX4720 sensitivity to the cells (Fig. 3A) . Conversely, Spry2 knockdown had no effect on The agarose gel separation results ensured the product specifi city. The RNA extracted from each cell line was examined for the presence of Spry2 RNA transcripts by RT-PCR. Spry2 cDNA was subjected to PCR analysis with specifi c primers to determine the expression of Spry2 and the human β-actin gene. The PCR-amplifi ed products were subjected to electrophoresis through a 1.2% agarose gel. www.biomolther.org PLX4720 sensitivity in the BRAF inhibitor-resistant SK-MEL-2 and A375P/Mdr cells, which showed weak expression of endogenous Spry2 (Fig. 3B, 3C) . Interestingly, the knockdown of Spry2 signifi cantly inhibited the growth of only BRAF V600E mutant-harboring A375P/Mdr cells among two drug-resistant cell lines, regardless of drug treatment.
Role of Raf-1 kinase in the rebound activation of ERK signaling in A375P/Mdr cells
Re-activation of the RAF/MEK/ERK pathway has been observed in mutant BRAF melanoma cell lines with acquired resistance to BRAF inhibitors after continuous culture in the presence of a BRAF inhibitor (Aplin et al., 2011) . As shown in Fig. 4A , long-term treatment with PLX4720 induced pERK reactivation following BRAF inhibition in A375P cells, indicating that the negative feedback induced by Spry2 may be bypassed in BRAF mutant-harboring melanoma cells due to the presence of the BRAF mutation. It has been reported that BRAF inhibition induces BRAF binding to Raf-1, leading to Raf-1 hyperactivation and consequently elevated MEK and ERK signaling (Heidorn et al., 2010) . Thus, siRNA-mediated Raf-1 knockdown was used to further test the hypothesis that Raf-1 kinase plays a positive role in the BRAF inhibitor-induced reactivation of MEK-ERK signaling. As observed in Fig.  4B , the siRNA-mediated knockdown of Raf-1 attenuated the rebound activation of ERK stimulated by PLX4720 in A375P 
DISCUSSION
BRAF inhibitors have recently shown therapeutic promise for the treatment of metastatic melanoma harboring BRAF mutations (Holderfi eld et al., 2014) . However, the therapeutic effi cacy of BRAF inhibitor therapy is short in many patients due to the onset of acquired resistance to oncogenic BRAF www.biomolther.org inhibitors . Re-activation of the MAPK pathway has been accepted as a mechanism that contributes to the mechanism of acquired resistance to BRAF inhibitors after continuous culture in the presence of a BRAF inhibitor (Aplin et al., 2011) . Sprouty proteins have previously been suggested as negative regulators of the MAPK pathway through interaction with Raf-1 (Gross et al., 2001) . Our previous study showed evidence that enhancement of Raf-1 kinase activity, which occurs in parallel with a decrease in the interaction with Spry2, may contribute to the development of acquired resistance in Ras-NIH 3T3 cells (Ahn et al., 2011) . Our fi ndings also suggested that Spry2 did not directly regulate Raf-1 kinase activity but rather acted as a scaffolding protein that assists interactions between Raf-1 kinase and its direct regulators (Ahn et al., 2010) . In this study, we found that Spry2 expression was higher in cells harboring the BRAF V600E mutation compared with cells with WT BRAF. This result is consistent with the results from other laboratories (Tsavachidou et al., 2004; Xu et al., 2010; Pratilas et al., 2012) and show that oncogenic BRAF mutations in melanoma lead to elevated Sprouty levels. This paradoxical overexpression of the feedback regulator Spry2 in BRAF V600E-harboring tumors can be attributed to the inability of Spry2 to inhibit BRAF V600E activity (Brady et al., 2009) . In fact, it has been found that Raf signaling is insusceptible to negative feedback in BRAF mutant-harboring tumors (Pratilas et al., 2009) . In transformed cells, increased MAPK/ERK activity is associated with increased output of the pathway, leading to enhanced expression of transcription factors and negative feedback regulators, such as Spry2 (Pratilas et al., 2009) . Constitutive activation of MAPK/ERK signaling by activated oncoproteins, such as BRAF V600E, is likely to result in constitutive negative feedback (Pratilas et al., 2009) . These data suggest that Spry2 may be bypassed in melanoma cells by the presence of BRAF mutations. In particular, oncogenic BRAF mutants, such as BRAF V600E, is believed to induce active kinase conformations and thereby prevent Sprouty2 binding (Brady et al., 2009) .
More interestingly, we found that Spry2 exhibits strongly reduced expression in A375P/Mdr cells with acquired resistance to BRAF inhibitors. Several researchers have reported that the Spry2 levels are markedly diminished after exposure to BRAF inhibitors in BRAF V600E cells (Joseph et al., 2010; Lito et al., 2012) . In addition, Spry2 overexpression partially restored sensitivity to the BRAF inhibitor PLX4720 in two BRAF inhibitor-resistant cell lines (SK-MEL-2 and A375P/ Mdr), irrespective of their BRAF mutational status. However, we found that the effect of Spry2 overexpression on cell proliferation was negligible in A375P cells. Although Spry2 ovrexpression caused a very weak but statistically signifi cant increase in cell proliferation of A375P cells at 1 μM of PLX4720, the actual difference in cell growth rate between mock-and Spry2 overexpressing A375P cells was just 6%. In contrast, in A375P/Mdr and SK-MEL-2 cell lines, the actual difference in cell growth rate was greater than 20%. This result implies that the downregulation of Spry2 plays a critical role in the acquired resistance to the BRAF inhibitor. However, in our study, Spry2 overexpression in A375P/Mdr cells resulted in no signifi cant change in the levels of pERK or pMEK. Lito et al. (Lito et al., 2012) also reported that the knockdown of Spry proteins does not affect EGFR-induced pERK. Unexpectedly, Spry2-silenced A375P cells were found to be more sensitive to BRAF inhibitors than control cells. Notably, a fi nding consistent with our results was reported by another research group that examined Spry2 feedback dysregulation in BRAF-mutant thyroid cancer (Dultz et al., 2013) . In their study, the BRAF mutant-harboring cells were found to be signifi cantly more sensitive to MAPK/ERK inhibition after Spry2 was knocked down by siRNA.
BRAF inhibition has been known to induce BRAF binding to Raf-1 in the presence of activated Ras, leading to Raf-1 hyperactivation and consequently paradoxical activation of MEK/ ERK signaling (Heidorn et al., 2010) . Our previous fi nding also showed that a BRAF inhibitor markedly induced the interaction between BRAF and Raf-1 proteins (Kim et al., 2012) . In this study, we also observed a marginal rebound after initial inhibition of ERK phosphorylation in A375P cells treated with PLX4720. It has been reported that ERK rebound is dependent on the expression of Raf-1 containing a dimer that is resistant to Raf inhibition (Lito et al., 2012) . In fact, we found that pERK rebound was signifi cantly reduced after Raf-1 expression was reduced by siRNA in A375P cells treated with RAF inhibitors, strongly suggesting the positive role of Raf-1 kinase in ERK reactivation in response to BRAF inhibition.
Our data suggest that the induction of resistance to a BRAF inhibitor in BRAF V600E-harboring cells can be attributed to the inability of Spry2 to inhibit BRAF V600E activity. In summary, in BRAF inhibitor-resistant BRAF V600E-harboring cells, RAF signaling may be released from negative feedback inhibition through interaction with Spry2, leading to ERK rebound and, consequently, the induction of acquired resistance to BRAF inhibitors.
